GGrantIndex
← Leaderboards

Charles Y.c Pak

University Of Texas Sw Med Ctr/Dallas

Google Scholar ↗PubMed ↗ORCID ↗
$11,557,463
Attributed
$11,557,463
Total exposure
20
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$28,557,498 · 22

By mechanism

M01$21,469,705 · 19
P01$6,887,818 · 2
K30$199,975 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Texas Sw Med Ctr/Dallas

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectNutrition Related TagHuman Therapy EvaluationCitratesOsteoporosisSlow Release DrugNephrolithiasisDrug Screening /EvaluationCalciumPharmacokineticsClinical TrialsMetabolism Disorder ChemotherapySkeletal Disorder ChemotherapyIngested Fluoride TherapyNutrient BioavailabilityBone DensityPhosphatesChemopreventionMagnesium IonPlacebosDrug Adverse EffectFemaleFluorine

Grant awards (66)

Formulation of Rational Therapy of Nephrolithiasis$1,463,525
P01 · FY2004 · DK
Comprehensive Evaluation of Osteoporosis$664
M01 · FY2004 · RR
Slow-Release Neutral Phosphate: Absorptive Hypercalciuria Correction$221
M01 · FY2004 · RR
GENERAL CLINICAL RESEARCH CENTER$3,076,374
M01 · FY2003 · RR
FORMULATION OF RATIONAL THERAPY OF NEPHROLITHIASIS$1,199,141
P01 · FY2003 · DK
GENERAL CLINICAL RESEARCH CENTER$2,796,869
M01 · FY2002 · RR
FORMULATION OF RATIONAL THERAPY OF NEPHROLITHIASIS$1,199,141
P01 · FY2002 · DK
PREVENTION OF K AND MG DEPLETION BY KMAG CITRATE$321,374
M01 · FY2002 · RR
K-MAG CITRATE DURING THIAZIDE TREATMENT FOR STONES$321,374
M01 · FY2002 · RR
CORRECTION OF THIAZIDE INDUCED HYPOKALEMIA AND HYPOMAGNESEMIA$321,374
M01 · FY2002 · RR
RANDOMIZED SLOW FLUORIDE TRIAL IN IDIOPATHIC OSTEOPOROSIS$321,374
M01 · FY2002 · RR
PREVENTION OF BONE LOSS IN EARLY POSTMENOPAUSAL WOMEN WITH CALCIUM$321,374
M01 · FY2002 · RR
COMPREHENSIVE EVALUATION OF OSTEOPOROSIS$321,374
M01 · FY2002 · RR
RANDOMIZED TRIAL OF UROPHOS-K IN ABSORPTIVE HYPERCALCIURIA$321,374
M01 · FY2002 · RR
PREVENTION OF BONE LOSS AND RENAL STONES DURING IMMOBILIZATION$321,374
M01 · FY2002 · RR
FLUORIDE BIOAVAILABILITY$321,374
M01 · FY2002 · RR
SLOW RELEASE NEUTRAL PHOSPHATE--ABSORPTIVE HYPERCALCIURIA CORRECTION$321,374
M01 · FY2002 · RR
INTEGRATED ASSESSMENT OF CALCIUM METABOLISM$321,374
M01 · FY2002 · RR
PHARMACOKINETIC PHARMACODYNAMIC ELUCIDATION OF UROPHOS K (SLOW RELEAS$321,374
M01 · FY2002 · RR
STONE FORMING RISK OF GRAPEFRUIT JUICE CONSUMPTION$321,374
M01 · FY2002 · RR
CALCIUM BIOAVAILABILITY FROM CALCIUM FORTIFIED ORANGE JUICE &MILK$321,374
M01 · FY2002 · RR
REFINED USES OF NEOSTEN IN OSTEOPOROSIS MANAGEMENT$321,374
M01 · FY2002 · RR
RANDOMIZED SLOW RELEASE SODIUM FLUORIDE AND CALCIUM CITRATE$321,374
M01 · FY2002 · RR
FLUORIDE BIOAVAILABILITY--NEOSTEN VS GENERIC FLUORIDE$321,374
M01 · FY2002 · RR
CORE--GENERAL ANALYTICAL LABORATORY$228,547
P01 · FY2002 · DK
GENERAL CLINICAL RESEARCH CENTER$2,306,787
M01 · FY2001 · RR
FORMULATION OF RATIONAL THERAPY OF NEPHROLITHIASIS$1,313,325
P01 · FY2001 · DK
PREVENTION OF K AND MG DEPLETION BY KMAG CITRATE$321,374
M01 · FY2001 · RR
PREVENTION OF BONE LOSS IN EARLY POSTMENOPAUSAL WOMEN WITH CALCIUM$321,374
M01 · FY2001 · RR
COMPREHENSIVE EVALUATION OF OSTEOPOROSIS$321,374
M01 · FY2001 · RR
INTEGRATED ASSESSMENT OF CALCIUM METABOLISM$321,374
M01 · FY2001 · RR
RANDOMIZED SLOW RELEASE SODIUM FLUORIDE AND CALCIUM CITRATE$321,374
M01 · FY2001 · RR
SLOW RELEASE NEUTRAL PHOSPHATE--ABSORPTIVE HYPERCALCIURIA CORRECTION$321,374
M01 · FY2001 · RR
FLUORIDE BIOAVAILABILITY$321,374
M01 · FY2001 · RR
PREVENTION OF BONE LOSS AND RENAL STONES DURING IMMOBILIZATION$321,374
M01 · FY2001 · RR
RANDOMIZED TRIAL OF UROPHOS-K IN ABSORPTIVE HYPERCALCIURIA$321,374
M01 · FY2001 · RR
RANDOMIZED SLOW FLUORIDE TRIAL IN IDIOPATHIC OSTEOPOROSIS$321,374
M01 · FY2001 · RR
CORRECTION OF THIAZIDE INDUCED HYPOKALEMIA AND HYPOMAGNESEMIA$321,374
M01 · FY2001 · RR
K-MAG CITRATE DURING THIAZIDE TREATMENT FOR STONES$321,374
M01 · FY2001 · RR
FLUORIDE BIOAVAILABILITY--NEOSTEN VS GENERIC FLUORIDE$321,374
M01 · FY2001 · RR
REFINED USES OF NEOSTEN IN OSTEOPOROSIS MANAGEMENT$321,374
M01 · FY2001 · RR
CALCIUM BIOAVAILABILITY FROM CALCIUM FORTIFIED ORANGE JUICE &MILK$321,374
M01 · FY2001 · RR
STONE FORMING RISK OF GRAPEFRUIT JUICE CONSUMPTION$321,374
M01 · FY2001 · RR
PHARMACOKINETIC PHARMACODYNAMIC ELUCIDATION OF UROPHOS K (SLOW RELEAS$321,374
M01 · FY2001 · RR
CORE--GENERAL ANALYTICAL LABORATORY$0
P01 · FY2001 · DK
GENERAL CLINICAL RESEARCH CENTER$2,327,236
M01 · FY2000 · RR
FORMULATION OF RATIONAL THERAPY OF NEPHROLITHIASIS$1,317,637
P01 · FY2000 · DK
TRAINING CURRICULUM IN PATIENT ORIENTED RESEARCH$199,975
K30 · FY2000 · HL
CORE--GENERAL ANALYTICAL LABORATORY$166,502
P01 · FY2000 · DK
STONE FORMING RISK OF GRAPEFRUIT JUICE CONSUMPTION$34,838
M01 · FY2000 · RR
CALCIUM BIOAVAILABILITY FROM CALCIUM FORTIFIED ORANGE JUICE &MILK$0
M01 · FY2000 · RR
REFINED USES OF NEOSTEN IN OSTEOPOROSIS MANAGEMENT$0
M01 · FY2000 · RR
FLUORIDE BIOAVAILABILITY--NEOSTEN VS GENERIC FLUORIDE$0
M01 · FY2000 · RR
PREVENTION OF K AND MG DEPLETION BY KMAG CITRATE$0
M01 · FY2000 · RR
K-MAG CITRATE DURING THIAZIDE TREATMENT FOR STONES$0
M01 · FY2000 · RR
FLUORIDE BIOAVAILABLITY--EFFECT OF STANDARD BREAKFAST &CITRACAL$0
M01 · FY2000 · RR
CORRECTION OF THIAZIDE INDUCED HYPOKALEMIA &HYPOMAGNESEMIA$0
M01 · FY2000 · RR
RANDOMIZED SLOW FLUORIDE TRIAL IN IDIOPATHIC OSTEOPOROSIS$0
M01 · FY2000 · RR
RANDOMIZED TRIAL OF UROPHOS-K IN ABSORPTIVE HYPERCALCIURIA$0
M01 · FY2000 · RR
PREVENTION OF BONE LOSS &NEPHROLITHIASIS DURING IMMOBILIZATION$0
M01 · FY2000 · RR
BIOAVAILABILITY OF SLOW-RELEASE SODIUM FLUORIDE$0
M01 · FY2000 · RR
CORRECTION OF ABSORPTIVE HYPERCALCIURIA W/ SLOW RELEASE NEUTRAL PHOSPHATE$0
M01 · FY2000 · RR
RANDOMIZED SLOW RELEASE SODIUM FLUORIDE &CALCIUM CITRATE$0
M01 · FY2000 · RR
AMBULAATORY &INPATIENT EVALUATION OF OSTEOPOROSIS$0
M01 · FY2000 · RR
PREVENTION OF BONE LOSS IN EARLY POSTMENOPAUSAL WOMEN W/ CALCIUM$0
M01 · FY2000 · RR
PHARMACOKINETIC PHARMACODYNAMIC ELUCIDATION OF UROPHOS K (SLOW RELEAS$0
M01 · FY2000 · RR